The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS)

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Yaba, Aylin ^a   Demir, Necdet ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Mouse; mTOR; Ovary; PCOS

Indexed keywords

ESTRADIOL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PRASTERONE; PROGESTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; GRANULOSA CELL; MOUSE; NONHUMAN; OVARY FOLLICLE CELL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THECA CELL;

EID: 84869863245     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-38     Document Type: Article

References (50)

1. Developmental origin of polycystic ovary syndrome-a hypothesis. Abbott DH, Dumesic DA, Franks S, J Endocrinol 2002 174 1 5 10.1677/joe.0.1740001 12098657
2. Expression of insulin-like growth factor (IGF), IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. Voutilainen R, Franks S, Mason HD, Martikainen H, J Clin Endocrinol Metab 1996 81 1003 1008 10.1210/jc.81.3.1003 8772565
3. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. Burger CW, Korsen T, van Kessel H, van Dop PA, Caron FJ, Schoemaker J, J Clin Endocrinol Metab 1985 61 1126 1132 10.1210/jcem-61-6-1126 3932449
4. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Berga SL, Yen SS, Clin Endocrinol (Oxf) 1989 30 177 184 10.1111/j.1365-2265.1989.tb03739.x
5. Polycystic ovary syndrome. Ehrmann DA, N Engl J Med 2005 352 1223 1236 10.1056/NEJMra041536 15788499
6. A practical approach to the diagnosis of polycystic ovary syndrome. Chang RJ, Am J Obstet Gynecol 2004 191 713 717 10.1016/j.ajog.2004.04.045 15467530
7. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A, J Clin Endocrinol Metab 1987 65 499 507 10.1210/jcem-65-3-499 3305551
8. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Adams J, Polson DW, Franks S, Br Med J (Clin Res Ed) 1986 293 355 359 10.1136/bmj.293.6543.355
9. The genetic basis of polycystic ovary syndrome. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M, Hum Reprod 1997 12 2641 2648 10.1093/humrep/12.12.2641 9455828
10. The development of the polycystic ovary syndrome: family history as a risk factor. Kahsar-Miller M, Azziz R, Trends Endocrinol Metab 1998 9 55 58 10.1016/S1043-2760(98)00021-6 18406241
11. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL, Endocr Rev 2005 26 251 282 15561799
12. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM, Lanzone A, Hum Reprod 2006 21 3108 3115 10.1093/humrep/del306 17053004
13. Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation. Sabatini ME, Guo L, Lynch MP, Doyle JO, Lee H, Rueda BR, Styer AK, J Ovarian Res 2011 4 8 10.1186/1757-2215-4-8 21605417
14. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Lee MT, Anderson E, Lee GY, Anat Rec 1991 231 185 192 10.1002/ar.1092310206 1836118
15. Cystogenesis of the ovarian antral follicle of the rat: ultrastructural changes and hormonal profile following the administration of dehydroepiandrosterone. Anderson E, Lee MT, Lee GY, Anat Rec 1992 234 359 382 10.1002/ar.1092340307 1443664
16. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, Chiocchio S, Cremaschi G, Motta AB, J Reprod Immunol 2004 64 59 74 10.1016/j.jri.2004.04.002 15596227
17. TOR signaling in growth and metabolism. Wullschleger S, Loewith R, Hall MN, Cell 2006 124 471 484 10.1016/j.cell.2006.01.016 16469695
18. Targeting the mTOR signaling network in cancer. Chiang GG, Abraham RT, Trends Mol Med 2007 13 433 442 10.1016/j.molmed.2007.08.001 17905659
19. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Tsang CK, Qi H, Liu LF, Zheng XF, Drug Discov Today 2007 12 112 124 10.1016/j.drudis.2006.12.008 17275731
20. The expanding TOR signaling network. Martin DE, Hall MN, Curr Opin Cell Biol 2005 17 158 166 10.1016/j.ceb.2005.02.008 15780592
21. TOR, a central controller of cell growth. Schmelzle T, Hall MN, Cell 2000 103 253 262 10.1016/S0092-8674(00)00117-3 11057898
22. Expanding mTOR signaling. Yang Q, Guan KL, Cell Res 2007 17 666 681 10.1038/cr.2007.64 17680028
23. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR, Biochem J 2007 405 513 522 10.1042/BJ20070540 17461779
24. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN, PLoS One 2007 2 1217 10.1371/journal.pone.0001217 18030348
25. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH, J Biol Chem 2007 282 25604 25612 10.1074/jbc.M704343200 17599906
26. The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Roa J, Garcia-Galiano D, Varela L, Sanchez-Garrido MA, Pineda R, Castellano JM, Ruiz-Pino F, Romero M, Aguilar E, Lopez M, Gaytan F, Dieguez C, Pinilla L, Tena-Sempere M, Endocrinology 2009 150 5016 5026 10.1210/en.2009-0096 19734277
27. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Yaba A, Bianchi V, Borini A, Johnson J, Reprod Sci 2008 15 128 138 10.1177/1933719107312037 18276949
28. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C, Motta AB, Mol Hum Reprod 2006 12 475 481 10.1093/molehr/gal057 16809378
29. Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Sander V, Luchetti CG, Solano ME, Elia E, Di Girolamo G, Gonzalez C, Motta AB, Reproduction 2006 131 591 602 10.1530/rep.1.00941 16514202
30. Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats. Aragno M, Brignardello E, Tamagno E, Gatto V, Danni O, Boccuzzi G, J Endocrinol 1997 155 233 240 10.1677/joe.0. 1550233 9415057
31. Dehydroepiandrosterone modulates nuclear factor-kappaB activation in hippocampus of diabetic rats. Aragno M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, Parola M, Danni O, Boccuzzi G, Endocrinology 2002 143 3250 3258 10.1210/en.2002-220182 12193536
32. Krev1 interaction trapped-1/cerebral cavernous malformation-1 protein expression during early angiogenesis. Guzeloglu-Kayisli O, Kayisli UA, Amankulor NM, Voorhees JR, Gokce O, DiLuna ML, Laurans MS, Luleci G, Gunel M, J Neurosurg 2004 100 481 487 15287459
33. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called «hyperthecosis» Hughesdon PE, Obstet Gynecol Surv 1982 37 59 77 10.1097/00006254-198202000-00001 7033852
34. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Jonard S, Dewailly D, Hum Reprod Update 2004 10 2 107 117 10.1093/humupd/dmh010 15073141
35. Exogenous androstenedione induces formation of follicular cysts and premature luteinization of granulosa cells in the ovary. Okutsu Y, Itoh MT, Takahashi N, Ishizuka B, Fertil Steril 2010 93 927 935 10.1016/j.fertnstert. 2008.10.064 19100535
36. Follicular dynamics in the polycystic ovary syndrome. Franks S, Mason H, Willis D, Mol Cell Endocrinol 2000 163 49 52 10.1016/S0303-7207(99)00239-7 10963873
37. Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Mendonca HC, Montenegro RM Jr, Foss MC, de Sa MF S, Ferriani RA, Braz J Med Biol Res 2004 37 729 736 10.1590/S0100- 879X2004000500015 15107936
38. Irregular cycles and steroid hormones in polycystic ovary syndrome. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA, Hum Reprod 2005 20 2402 2408 10.1093/humrep/dei093 15932911
39. Follicle dynamics and anovulation in polycystic ovary syndrome. Franks S, Stark J, Hardy K, Hum Reprod Update 2008 14 4 367 378 Epub 2008 May 22. Review. Erratum in: Hum Reprod Update. 2008 Sep-Oct;14(5):539. PMID: 18499708 [PubMed-indexed for MEDLINE 10.1093/humupd/dmn015 18499708
40. Oocyte-granulosa-theca cell interactions during preantral follicular development. Orisaka M, Tajima K, Tsang BK, Kotsuji F, J Ovarian Res 2009 2 1 9 PMID: 19589134 [PubMed] 10.1186/1757-2215-2-9 19589134
41. The amino acid sensitive TOR pathway from yeast to mammals. Dann SG, Thomas G, FEBS Lett 2006 580 2821 2829 10.1016/j.febslet.2006.04.068 16684541
42. TOR signaling. Harris TE, Lawrence JC Jr, Sci STKE 2003 2003 e15 14668532
43. Upstream and downstream of mTOR. Hay N, Sonenberg N, Genes Dev 2004 18 1926 1945 10.1101/gad.1212704 15314020
44. Signaling by target of rapamycin proteins in cell growth control. Inoki K, Ouyang H, Li Y, Guan KL, Microbiol Mol Biol Rev 2005 69 79 100 10.1128/MMBR.69.1.79-100.2005 15755954
45. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Kwiatkowski DJ, Manning BD, Hum Mol Genet 2005 14 Spec No. 2 251 R258 16244323
46. Growing roles for the mTOR pathway. Sarbassov DD, Ali SM, Sabatini DM, Curr Opin Cell Biol 2005 17 596 603 10.1016/j.ceb.2005.09.009 16226444
47. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. Bachmann RA, Kim JH, Wu AL, Park IH, Chen J, J Biol Chem 2006 281 7357 7363 10.1074/jbc.M512218200 16407298
48. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS, Hunzicker-Dunn M, J Biol Chem 2004 279 19431 19440 10.1074/jbc.M401235200 14982927
49. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL, EMBO J 2008 27 1919 1931 10.1038/emboj.2008.119 18566587
50. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. van der Spuy ZM, Dyer SJ, Best Pract Res Clin Obstet Gynaecol 2004 18 755 771 15380145